Author

B. Chong

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Efficacy and safety of litifilimab in cutaneous lupus erythematosus: 24-week results of the randomized phase 2 study, AMETHYST.

BACKGROUND Cutaneous lupus erythematosus (CLE) is a serious autoimmune disease with no approved targeted treatments. OBJECTIVE Evaluate the efficacy and safety of litifilimab in AMETHYST Part A (Phase 2). METHODS AMETHYST is a randomized, double-blind, placebo-controlled, Phase 2/3 study that investigates litifilim...

J. Merola, Victoria P. Werth, B. Chong et al. · Journal of American Academy... · 0 citations

Open access Aug 2026

Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial.

Importance Brepocitinib, a first-in-class oral, selective TYK2 and JAK1 inhibitor, demonstrated broad efficacy in a phase 3 randomized clinical trial in dermatomyositis. Objective To evaluate the effects of brepocitinib on cutaneous disease activity, itch, skin-related quality of life (QOL), and achievement of remiss...

Aaron R. Mangold, A. Haemel, Neda Shahriari et al. · JAMA dermatology · 1 citation